Trex Company, Inc. (NYSE:TREX) reported Q3 earnings that were ahead of analysts' estimates and gave a guidance for Q4 sales that was in line with the Street's expectations. Trex Company, Inc. (NYSE:TREX) is trading above the mid-point of the 52-week range between $25.14 and $43.42. The maker of wood-alternative decking and railing products said earnings rose to $8.9 million or $0.28 per diluted share from a loss of 15.3 million or $0.45 the year earlier. The Q313 quarter was weighed down by a $22.9 million in charges, related among others to warranty reserve for decking material manufactured at its Nevada plant prior to 2007. The analyst consensus called for earnings of $0.24 per share, according to Capital IQ. Sales in Q3 rose 32% to $95.5 million, exceeding the $91.9 million consensus. For Q4, Trex is expecting revenue of $70 million compared to the $70.2 million average estimate.Tenneco Inc (NYSE:TEN) a producer of emission control and ride control products, reported Q3 results that beat the Street view on EPS and revenues in line with expectations. The company reported Q3 adjusted EPS of $1.25, up from $0.99 in Q3 2013 and beating analyst estimates of $1.08. Total revenues of $2.08 billion were up from $1.96 billion in Q3 2013 and in line with analyst estimates of $2.08 billion for the quarter. The sales increase includes higher revenues in both product lines with Clean Air increasing 8% and Ride Performance up 2%. In Q4 the company anticipates that higher light vehicle unit volumes and higher commercial truck and off-highway content will counteract an estimated 3% of total revenue currency headwind, resulting in total revenue about the same to slightly higher compared with Q4 last year. Shares of Tenneco Inc (NYSE:TEN) are at $54.56 within a 52-week range of $46.64 - $69.22.Zogenix, Inc. (NASDAQ:ZGNX) said it has acquired privately held U.K.-based pharmaceutical company Brabant Pharma for $20 million in cash and $15 million in stock plus potential future milestone and royalty payments of up to a total $95 million. The acquisition includes worldwide development and commercialization rights to Brabafen, low-dose fenfluramine, for the treatment of Dravet syndrome, a rare and catastrophic form of intractable epilepsy that begins in infancy. The drug recently received orphan drug designation in Europe and the U.S. for the treatment of Dravet syndrome. The first milestone payment is not anticipated until late 2016 upon submission of the New Drug Application for Brabafen.Zogenix said that the latest results show that 93% of patients were either seizure-free or had greatly reduced seizure frequency, during an average treatment period of greater than 12 years. "This is a transformational acquisition for Zogenix," CEO Roger Hawley said in a statement. "The addition of Brabant's Dravet syndrome program significantly enhances our CNS development pipeline." Zogenix, Inc. (NASDAQ:ZGNX) closed higher 0.8% on Friday, near the lower end of the 52-week range between $1.07 and $5.19.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
